Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Levin NJ, Seger EW, Neill BC, Wang T, et al. Cutis 2023;112:E16-E17.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Levin NJ, Seger EW, Neill BC, Wang T, et al. Dupilumab for Dyshidrotic Eczema With Secondary Improvement in Eosinophilic Interstitial Lung Disease. Cutis 2023;112:E16-E17.
PMID: 38091430